Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 10 clinical trials
A Phase 1 Study With ABBV-CLS-484 in Subjects With Locally Advanced or Metastatic Tumors

subjects with locally advanced or metastatic, relapsed or refractory head and neck squamous cell carcinoma (HNSCC), relapsed or refractory non-small cell lung cancer (NSCLC), and advanced clear cell renal

  • 13 views
  • 08 Jul, 2022
  • 8 locations
First In Human Study With ABBV-CLS-579 When Given Alone and In Combination In Participants With Locally Advanced Or Metastatic Tumors

locally advanced or metastatic, relapsed or refractory head and neck squamous cell carcinoma (HNSCC), relapsed or refractory non-small cell lung cancer (NSCLC), and advanced clear cell renal cell

  • 78 views
  • 28 Jul, 2022
  • 8 locations
Study of BO-112 With Radiotherapy and Nivolumab for Metastatic Refractory NSCLC (Noelia)

This is a study of repeated IT administrations of BO-112 in combination with ablative radiotherapy (SABR) and concurrent nivolumab in patients with metastatic PD-1/PD-L1-refractory NSCLC.

  • 0 views
  • 27 Jul, 2022
  • 1 location
Dupilumab_Metastatic NSCLC

. For Phase 2, to determine the effect of adding IL-4Ra blockade to PD-(L)1 blocking agents in patients with relapsed/refractory NSCLC, who have progressed on prior PD-(L)1 agents

  • 0 views
  • 16 Oct, 2021
  • 1 location
Atezolizumab and Cobimetinib in Treating Patients With Metastatic, Recurrent, or Refractory Non-small Cell Lung Cancer

This phase II trial studies how well atezolizumab and cobimetinib work in treating patients with non-small cell lung cancer that has spread to other places in the body (metastatic), has come back (recurrent), or does not respond to treatment (refractory). Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the …

measurable disease
ct scan
lung cancer
cancer
monoclonal antibodies
  • 54 views
  • 21 Jul, 2022
  • 7 locations
Ph I/II Trial of Systemic VSV-IFN -NIS and Pembrolizumab in Refractory NSCLC and NEC

expansion portion will use one-sample binomial designs to assess the efficacy of the combination in patients with refractory NSCLC or NEC. The optimal dose (RP2D) determined in the dose escalation portion

stage iv non-small cell lung cancer
measurable disease
cancer
pembrolizumab
cancer chemotherapy
  • 7 views
  • 20 Oct, 2021
  • 1 location
Dexamethasone Effects in Patients With Refractory Non-Small Cell Lung Cancer Using FLT Positron Emission Tomography

This pilot research trial studies the effects of dexamethasone in patients with non-small cell lung cancer that has not responded after previous treatment. Drugs such as dexamethasone can affect how tumors grow and respond to treatments. Imaging tests, such as fluoro-L-thymidine (FLT) positron emission tomography , use a small amount …

biomarker analysis
lung cancer
corticosteroids
cancer
diabetes
  • 12 views
  • 27 Apr, 2022
  • 1 location
Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC)

combination with low-dose cyclophosphamide, Cohort 2: PD-1 relapsed/refractory melanoma, and Cohort 3: PD-1 relapsed/refractory NSCLC.

measurable disease
EGFR
targeted therapy
pembrolizumab
squamous cell carcinoma
  • 0 views
  • 27 Apr, 2022
  • 1 location
A Randomised Trial of Chemotherapy Plus Surgery for Recurrent Non-Small Cell Lung Cancer (CCODG-NSCLC)

clinical oncology, either a single format or given as combinations followed by surgery are effective in the treatment of relapsed and refractory non-small cell lung cancer patients.

docetaxel
lung cancer
cancer chemotherapy
carboplatin
  • 1 views
  • 11 May, 2022
  • 3 locations
A Study of CM24 in Combination With Nivolumab in Adults With Advanced Solid Tumors

-small cell lung cancer (NSCLC) (Part B), and metastatic pancreatic cancer (Part C) to evaluate the safety and tolerability of CM-24 in combination with nivolumab. In Part C of the study nab-paclitaxel

measurable disease
lung cancer
5-fluorouracil
cancer
nivolumab
  • 10 views
  • 12 May, 2022
  • 6 locations